Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 9/20 | 0.47 |
| ▸ | NPY4R | P50391 | 7/20 | 0.42 |
| ▸ | NPY1R | P25929 | 5/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28776590 | 1.00 | ENPEP (0.47) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL3780306 | 1.00 | ENPEP (0.47) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30968271 | 0.97 | ENPEP (0.46) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31074246 | 0.96 | ENPEP (0.49) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30686008 | 0.94 | ENPEP (0.43) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31174192 | 0.94 | NPY4R (0.50) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31174188 | 0.94 | NPY4R (0.50) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30686006 | 0.94 | ENPEP (0.43) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30631320 | 0.93 | NPY4R (0.41) | ENPEPNPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL22089839 | 0.91 | NPY4R (0.50) | ENPEPNPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| CN-118660707-A | Supermolecule self-assembly system | 北京睿创康泰医药研究院有限公司 | 2024-09-17 | — | — | CN | claimed |
| WO-2024162422-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | ハウス食品グループ本社株式会社 | 2024-08-08 | — | — | WO | claimed |
| CN-118291569-A | Yellow chicken oligopeptide and preparation method and application thereof | 中国食品发酵工业研究院有限公司 | 2024-07-05 | — | — | CN | claimed |
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12618841-B2 | Methods of diagnosing malignant diseases | ST INNOVATIVE DIAGNOSTICS LTD (IL) | 2026-05-05 | — | — | US | disclosed |
| EP-4534092-B1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260098080-A1 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | EVOLVERITAS BIOTECHNOLÓGIAI KORLÁTOLT FELELOSSÉGU TÁRSASÁG (HU) | 2026-04-09 | — | — | US | disclosed |
| US-12595485-B2 | Modulation of prekallikrein (PKK) expression | IONIS PHARMACEUTICALS, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260085097-A1 | DARPIN-CONTAINING COMPOSITIONS AND METHODS THEREOF | TEXAS A & M UNIV SYS (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260062498-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | OMEROS CORP (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4702987-A1 | COMBINED USE OF BISPECIFIC ANTIBODY BINDING TO ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X WITH BLOOD COAGULATION FACTOR X FOR TREATING SUBJECT WITH HEMOPHILIA A | Public University Corporation Nara Medical University (JP) | 2026-03-04 | — | — | EP | disclosed |
| US-5702938-A | Human tissue plasminogen activator | GENETECH, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5587159-A | POLYPEPTIDES | GENENTECH, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| EP-0093619-B2 | Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and DNA and transformed cell intermediates therefor | GENENTECH INC (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5185259-A | Recombinant human tissue plasminogen activator of high purity | GENENTECH, INC. (US) | 1993-02-09 | — | — | US | disclosed |
| EP-0093619-B1 | HUMAN TISSUE PLASMINOGEN ACTIVATOR, PHARMACEUTICAL COMPOSITIONS CONTAINING IT, PROCESSES FOR MAKING IT, AND DNA AND TRANSFORMED CELL INTERMEDIATES THEREFOR | GENENTECH, INC. (US) | 1989-09-13 | — | — | EP | disclosed |
| US-4853330-A | Human tissue plasminogen activator | GENENTECH, INC. (US) | 1989-08-01 | — | — | US | disclosed |
| US-4766075-A | FROM CELL CULTURES USING RECOMBITANT DNA | GENENTECH, INC. (US) | 1988-08-23 | — | — | US | disclosed |
| EP-0093619-A1 | Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and DNA and transformed cell intermediates therefor | GENENTECH, INC. (US) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146252-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, FUT6 | ENPEP 1580/4885NPY4R 2752/4885NPY1R 1953/4885 |
| US-20260098080-A1 | A MODIFIED PROTEIN SCAFFOLD AND USE THEREOF | MLX, HAX1, TPX2 | ENPEP 2395/4885NPY4R 607/4885NPY1R 522/4885 |
| US-12595485-B2 | Modulation of prekallikrein (PKK) expression | KLKB1, KLK1, KLK8 | ENPEP 755/4885NPY4R 1549/4885NPY1R 1439/4885 |
| US-20260085097-A1 | DARPIN-CONTAINING COMPOSITIONS AND METHODS THEREOF | FMNL1, ACTL6A, ANKK1 | ENPEP 1827/4885NPY4R 1707/4885NPY1R 2141/4885 |
| US-20260062498-A1 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | MASP2, C1QBP, C1S | ENPEP 736/4885NPY4R 3674/4885NPY1R 3345/4885 |
| US-12618841-B2 | Methods of diagnosing malignant diseases | FGB, F2, TFPI2 | ENPEP 909/4885NPY4R 4282/4885NPY1R 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.